Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates ...

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...